



## Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective 7/20/2017, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

- **Butrans, Pataday and Strattera** will be **added** to the program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- **Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.**
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

### IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of '1'; **Pharmacies can submit any valid NCPDP field (408-D8) value.**

**List of Brand Name Drugs included in this program\* (Updated): 6/21/2017**

Adderall XR	Focalin	<b>Strattera</b>
Aggrenox	Focalin XR	Tazorac cream
Alphagan P 0.15%	Gleevec	Tegretol suspension
Benzaclin pump, gel	Hepsera	Tegretol XR
<b>Butrans</b>	Kapvay	Tobradex suspension
Catapres-TTS	Myfortic	Trizivir
Cellcept suspension	<b>Pataday</b>	Valcyte tablet, solution
Copaxone 20mg SQ	Patanase	Voltaren Gel
Diastat	Protopic	Xeloda
Differin	Pulmicort Respules	Xenazine
Edecrin	Retin-A cream, gel	Zyflo CR
Exelon Patch	Seroquel XR	

\*List is subject to change

**Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.**